Prevalence of potential drug-drug interactions in patients of the Swiss HIV Cohort Study in the era of HIV integrase inhibitors

SPECIAL REPORT

HIV / AIDS

11. Konferenz der Internationalen AIDS-Gesellschaft (IAS) 2021

HIV / AIDS

Chemsex drugs on the rise: a longitudinal analysis of the Swiss HIV Cohort Study from 2007 to 2017

HIV Med.

Hampel B, Kusejko K, Kouyos RD, Böni J, Flepp M, Stöckle M, Conen A, Béguelin C, Künzler-Heule P, Nicca D, Schmidt AJ, Nguyen H, Delaloye J, Rougemont M, Bernasconi E, Rauch A, Günthard HF, Braun DL, Fehr J, Swiss HIV Cohort Study group.

doi: 10.1111/hiv.12821.

HIV / AIDSDrug Resistance

Emergence of drug resistance in the Swiss HIV Cohort Study under potent antiretroviral therapy is observed in socially disadvantaged patients

Clin Infect Dis.

Abela IA, Scherrer AU, Böni J, Yerly S, Klimkait T, Perreau M, Hirsch HH, Furrer H, Calmy A, Schmid P, Cavassini M, Bernasconi E, Günthard HF; Swiss HIV Cohort Study

doi: 10.1093/cid/ciz178.

HIV / AIDS

Aging does not impact drug-drug interaction magnitudes with antiretrovirals: a Swiss HIV Cohort Study

AIDS.

Stader F, Decosterd L, Stoeckle M, Cavassini M, Battegay M, Saldanha SA, Marzolini C, Courlet P, and the Swiss HIV Cohort Study

doi: 10.1097/QAD.0000000000002489.

HIV / AIDS

Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort

HIV Med

Fabbiani M, Rossetti B, Ciccullo A, Oreni L, Lagi F, Celani L, Colafigli M, De Vito A, Mazzitelli M, Dusina A, Durante M, Montagnani F, Rusconi S, Capetti A, Sterrantino G, D'Ettorre G, Di Giambenedetto S, ODOACRE Study Group.

doi: 10.1111/hiv.13146

HIV / AIDS

Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging patients enrolled in the Swiss HIV Cohort Study

AIDS.

Courlet P, Stader F, Guidi M, Saldanha SA, Stoeckle M, Cavassini M, Battegay M, Buclin T, Decosterd LA, Marzolini C, Swiss HIV Cohort Study.

doi: 10.1097/QAD.

HIV / AIDS

Differences in social and mental well-being of long-term survivors among people who inject drugs and other participants in the Swiss HIV Cohort Study: 1980-2018

Antivir Ther.

Kusejko K, Marzel A, Nguyen H, Chaudron SE, Bachmann N, Weber R, Bruggmann P, Roth JA, Bernasconi E, Calmy A, Cavassini M, Bregenzer A, Böni J, Yerly S, Klimkait T, Perreau M, Walti LN, Günthard HF, Kouyos RD, Swiss HIV Cohort Study.

doi: 10.3851/IMP3347.

HIV / AIDS

The comparative effectiveness of NRTI-sparing dual regimens in emulated trials using observational data from the Swiss HIV Cohort Study

Antivir Ther.

Young J, Scherrer AU, Calmy A, Tarr PE, Bernasconi E, Cavassini M, Hachfeld A, Vernazza P, Günthard HF, Bucher HC, Swiss HIV Cohort Study

doi: 10.3851/IMP3310.

HIV / AIDS

Polypharmacy, Drug-Drug Interactions, and Inappropriate Drugs: New Challenges in the Aging Population With HIV

doi: 10.1093/ofid/ofz531.

Related content

11. Konferenz der Internationalen AIDS-Gesellschaft (IAS) 2021

Chemsex drugs on the rise: a longitudinal analysis of the Swiss HIV Cohort Study from 2007 to 2017

Emergence of drug resistance in the Swiss HIV Cohort Study under potent antiretroviral therapy is observed in socially disadvantaged patients

Aging does not impact drug-drug interaction magnitudes with antiretrovirals: a Swiss HIV Cohort Study

Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort

Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging patients enrolled in the Swiss HIV Cohort Study

Differences in social and mental well-being of long-term survivors among people who inject drugs and other participants in the Swiss HIV Cohort Study: 1980-2018

The comparative effectiveness of NRTI-sparing dual regimens in emulated trials using observational data from the Swiss HIV Cohort Study

Polypharmacy, Drug-Drug Interactions, and Inappropriate Drugs: New Challenges in the Aging Population With HIV